Calidi Biotherapeutics Cuts Net Loss to $3.6M in Q3 2026

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) reported on 13 November 2026 a third-quarter net loss attributable to common stockholders of $3.6 million, or $1.47 per share, against a $10.8 million loss a year earlier. Cash and restricted cash totaled roughly $4.2 million at 30 September 2026, down from about $5.8 million at 31 December 2025.

Context — why the Q3 2026 print matters for CLDI

The headline swing is mostly accounting. The third quarter of 2025 carried a $5.7 million non-cash charge for a deemed dividend on warrants, and the company reported no such charge in the 2026 period. Strip that out and the operating picture is narrower but still improving: total operating expenses fell to $4.3 million from $5.0 million.

The reduction came almost entirely from the back office. General and administrative costs dropped $1.0 million, or 39%, year over year, and are down $3.6 million, or 42%, across the first nine months. Research and development moved the other way, rising to $2.7 million from $2.4 million as the lead program advanced.

That split is the story. Calidi is a clinical-stage biotechnology company with no product revenue, so its valuation rests on pipeline milestones rather than earnings. Cost discipline buys time; it does not create value on its own. The company said on 6 November 2026 it executed a restructuring plan, mostly through headcount reductions, that it expects to save $3 million annualized.

Management framed the move as extending the operating runway and preserving capital while pursuing additional financing. For a company of this size, that language points to a funding gap rather than a strategic pivot.

The quarter also included a $1.2 million gross at-the-market registered direct offering that closed on 18 September 2026. The company did not disclose the per-share price, the number of shares issued, or the identity of the purchasers.

Data — the numbers behind the CLDI quarter

The income statement shows a $3.6 million net loss on $4.3 million of operating expenses, offset by $708,000 of total other income. That other-income line included $681,000 of miscellaneous other income and a $59,000 favorable swing in the fair value of derivatives.

Metric	Q3 2026	Q3 2025
Net loss to common stockholders	$3.6M	$10.8M
Loss per share	$1.47	$35.25
R&D expense	$2.7M	$2.4M
G&A expense	$1.6M	$2.7M
Weighted average shares	2.476M	0.307M

The share count is the number that reframes the per-share loss. Weighted average shares outstanding rose roughly eightfold year over year, which is why a 66% smaller net loss translated into a 96% smaller per-share loss. Existing holders absorbed that dilution.

On the balance sheet, total assets fell to $5.5 million from $8.9 million at year-end 2025. Total liabilities declined to $3.9 million from $5.1 million, and total equity dropped to $1.6 million from $3.8 million. The operating lease right-of-use asset shrank to $83,000 from $1.7 million, and operating lease liabilities fell in step.

Cash burn is the constraint. Cash fell by about $1.7 million over nine months, but the quarterly figure is lumpier than that average suggests, given the September raise.

Analysis — what the CLD-401 data means for the sector

The pipeline news is where the science sits. Calidi said it presented two posters at the ESMO Congress 2026 on 24 October 2026 covering its RedTail platform, an engineered enveloped oncolytic virus designed for systemic delivery. The lead candidate, CLD-401, is in IND-enabling studies and targets metastatic non-small cell lung cancer and head and neck cancer.

The company reported that CLD-401 produced complete tumor eradication in 80% of EMT6 breast cancer tumor-bearing mice, versus 0% in the control arm. It also said new data from an MB49 bladder cancer model showed the candidate retained antitumor activity whether given intravenously or intratumorally.

Those are preclinical results in mice, not human data, and the company said so by describing the program as still moving toward the clinic. Mouse tumor-eradication rates have historically translated poorly into human response rates across oncology, which is the central caveat for anyone reading the ESMO headlines as a de-risking event.

The in situ T-cell engager platform is earlier still. Calidi said intravenous delivery generated approximately 10 ng/mL of EpCAM-targeted TCE directly within tumors, with both CLD-501 (TROP-2) and CLD-502 (EpCAM) showing antigen-dependent, dose-responsive T-cell-mediated cytotoxicity. Dose-response in a dish is a mechanism signal, not an efficacy signal.

For positioning, this is a micro-cap with a $1.6 million equity base, a going-concern-adjacent cash position, and a pipeline that needs partner or market funding to reach a first-in-human study. The flow is retail and specialist biotech money; institutional ownership at this market capitalization is typically thin. The restructuring and the ATM raise both point the same direction: the company is buying months, not years.

Outlook — what to watch next for CLDI

The nearest catalyst is the transition of CLD-401 from IND-enabling studies into a filed investigational new drug application, which the company has framed as the next step but has not dated. A second is any additional financing, given $3.9 million of cash against a research budget running near $2.7 million a quarter.

The $3 million annualized restructuring savings, if realized on the stated timeline, would extend the runway but not by itself close the gap to a clinical trial. The company did not quantify the number of roles cut or the one-time cost of the restructuring.

There is no analyst price target, moving average, or peer multiple in the report to anchor a level, and the company gave no revenue guidance because it has no product revenue. Watch the cash line each quarter and any 8-K disclosing new capital.

Frequently Asked Questions

Why did Calidi's net loss shrink so much in Q3 2026?

Most of the improvement is a base effect. The third quarter of 2025 included a $5.7 million non-cash deemed dividend on warrants that did not repeat. The rest came from cost cuts: G&A fell $1.0 million, or 39%, and total operating expenses fell to $4.3 million from $5.0 million. Research and development spending actually rose, to $2.7 million from $2.4 million.

What did the ESMO 2026 data actually show for CLD-401?

Calidi reported complete tumor eradication in 80% of EMT6 breast cancer tumor-bearing mice, against 0% in the control arm. In an MB49 bladder cancer model, the candidate retained activity with either intravenous or intratumoral dosing. These are preclinical mouse results. The program remains in IND-enabling studies and has not entered human trials.

Does Calidi have enough cash to fund its pipeline?

The company ended September 2026 with $3.9 million in cash and $0.2 million in restricted cash, down from $5.6 million in cash at year-end 2025. It raised $1.2 million gross in a September offering and expects $3 million in annualized savings from a November restructuring. Management said the cuts are meant to extend the runway while it pursues additional financing.

Bottom Line

Calidi cut its quarterly loss and its cost base, but $3.9 million of cash against a $2.7 million quarterly research budget leaves the pipeline dependent on the next raise.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.